Gastroenterology

Fujifilm to Unveil New Medical Imaging Advances at the RSNA 2022 Conference

Retrieved on: 
Monday, November 21, 2022
Heart, Architecture, McCormick Place, Diagnosis, Tomosynthesis, Health, Laboratory, Gastroenterology, Anatomy, Mammography, AI, Digital radiography, Hospital, RSNA, Knowledge, Acquisition, Algorithm, Spine, Radiological Society of North America, ISS, Electricity, X-ray, MRI, Artificial intelligence, CEDM, Sale, OEM, Scoliosis, Google Images, CT scan, Radiology, DBT, FDR, Lithium, CT, Nursing, FDA, Enterprise imaging, Medical imaging, Renewable energy, Innovation, Fujifilm

When healthcare professionals are trying to diagnose medical conditions, imaging can provide a more accurate picture of what is going on inside the patients body.

Key Points: 
  • When healthcare professionals are trying to diagnose medical conditions, imaging can provide a more accurate picture of what is going on inside the patients body.
  • To learn more about Fujifilms presence at RSNA 2022 and to schedule an on-site meeting, please click here.
  • Fujifilms innovative medical imaging portfolio includes solutions for digital radiography, mammography, CT, MRI, ultrasound, gastroenterology, pulmonology, endosurgery, and minimally invasive surgery.
  • The award-winning Synapse Enterprise Imaging portfolio provides healthcare professionals with the cross-departmental imaging and data access needed to deliver a complete patient record.

Motus GI Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 14, 2022
Blood, Hospital, American College, 2021 Essex County Council election, Endoscopy, Motus, EVS, Physician, Multisourcing, Mortality, Growth, ACG, Research, American College of Gastroenterology, State, Diagnosis, MD, Patient, Pharmaceutical industry, Renewable energy, Gastroenterology

We reported revenue in the third quarter of $278,000, which represents an approximately 50% increase compared with the second quarter of 2022, and our highest quarterly revenue to date.

Key Points: 
  • We reported revenue in the third quarter of $278,000, which represents an approximately 50% increase compared with the second quarter of 2022, and our highest quarterly revenue to date.
  • Financial Results for the Third Quarter Ended September 30, 2022
    The Company reported revenue of $278,000 for the third quarter 2022, compared to $141,000 for the same period last year.
  • After the third quarter end, the Company sold approximately $5.5 million worth of shares from its existing at-the-market facility.
  • As a result, the Companys current cash balance allows it to meet anticipated needs through the second quarter 2023.

CONMED Corporation to Participate in a Fireside Chat at the 34th Annual Piper Sander Healthcare Conference

Retrieved on: 
Tuesday, November 22, 2022
Health Technology, Health, Surgery, Medical Devices, Elective surgery, Surgeon, Software, Sumathi Best Television Current Reporting Award, Risk, Gynaecology, Government, Conference, NYSE, Gastroenterology, Chairperson, General surgery, Physician, Annual report, COVID-19, Special-purpose acquisition company, Risk management

CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 34th Annual Piper Sander Healthcare Conference at 3:30 p.m.

Key Points: 
  • CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 34th Annual Piper Sander Healthcare Conference at 3:30 p.m.
  • A live audio webcast of the fireside chat will be accessible through the Investors section of the Companys website at www.conmed.com and will be available for replay following the event.
  • CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures.
  • The Companys products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology.

EndoGastric Solutions, Inc.® Develops Reflux-Friendly Cookbook to Promote GERD Awareness Week

Retrieved on: 
Monday, November 21, 2022
General Health, Medical Devices, Other Health, Health, Fitness & Nutrition, Proton, Universal Health Services, Heartburn, PPI, Degenerative disease, Conditional sentence, EGS, GEV, Chest pain, Gastroenterology, Mouth, Gastroesophageal reflux disease, Diet, Marketing, Esophagitis, Safety, FACS, Asthma, Physician, Nissen fundoplication, Inflammation, Esophageal cancer, Esophagus, Stomach, Regurgitation, Gastrointestinal disease, Internet, Chronic cough, Rotation, Risk, Communication, Patient, Pharmaceutical industry, Medical device, GERD, MD

EndoGastric Solutions, Inc. today announced the companies national campaign, GERD Gourmet; Recipes for Reflux, supporting GERD Awareness Week, November 20th-26th.

Key Points: 
  • EndoGastric Solutions, Inc. today announced the companies national campaign, GERD Gourmet; Recipes for Reflux, supporting GERD Awareness Week, November 20th-26th.
  • The International Federation for Gastrointestinal Diseases (IFFGD) designated Gerd Awareness Week as a time for encouraging individuals experiencing GERD symptoms to consult their physician and seek out information and support regarding the condition.
  • The first line of treatment for patients with GERD is often to make lifestyle changes, including diet and scheduled eating times.
  • GERD Awareness Week is the ideal time to remind patients that they should take their GERD symptoms seriously.

Shionogi, Active Citizenship Network and MEPS Advocate for Urgent Policy Implementation in EU Member States at EU Parliament Event to Address the Growing Threat of Antimicrobial Resistance

Retrieved on: 
Monday, November 21, 2022
Biotechnology, Infectious Diseases, Hospitals, Health, Pharmaceutical, Benchmark, Member of the European Parliament, Marketing, AMR, European Commission, Central nervous system disease, Royal commission, Senior, World Health Organization, Council, WHO, Infection, HERA, Cleveland Clinic Journal of Medicine, Vulnerable, Gastroenterology, Environmental health, Lancet, Antimicrobial resistance, Medicine, Policy, CNS, European, Research, Bankruptcy, Degenerative disease, Transplant, Pain, Council Implementing Regulation (EU) No. 282/2011, Death, European Parliament, Health, Access, Patient, Pharmaceutical industry, Renewable energy, Risk management, EU, Shionogi

The event reinforced the need for urgent attention and collaboration from pharmaceutical companies, policy stakeholders and governments to bring about policy change and innovation to address this growing issue.

Key Points: 
  • The event reinforced the need for urgent attention and collaboration from pharmaceutical companies, policy stakeholders and governments to bring about policy change and innovation to address this growing issue.
  • The event also explored collaborative and governance models to achieve better implementation of actions and best practices for a holistic AMR approach.
  • The meeting was crucial to increase awareness of Antimicrobial Resistance and the need for new innovations to address unmet needs.
  • Apr 2013; 80(4): 22533
    4 Antimicrobial Resistance Benchmark 2021. https://accesstomedicinefoundation.org/media/uploads/downloads/61ee760d0... Last accessed November 2022
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221120005048/en/

Escient Pharmaceuticals Initiates Phase 2 PACIFIC Study Evaluating EP547, An Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus

Retrieved on: 
Thursday, November 17, 2022
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Trial of the century, Primary biliary cholangitis, Skin, Primary sclerosing cholangitis, Bilirubin, PBC, PK, Itch, Cholestatic pruritus, Doctor of Philosophy, FRCP, Safety, PSC, MRGPRX4, Division, Therapy, Neuron, University, Hepatology, MRGPRX2, MD, University of Toronto, Patient, Pharmaceutical industry, Tourism, Gastroenterology

The Phase 2 study, PACIFIC, is a randomized, double-blind, placebo-controlled study designed to assess the efficacy, safety and tolerability of EP547 in subjects with cholestatic pruritus due to primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC).

Key Points: 
  • The Phase 2 study, PACIFIC, is a randomized, double-blind, placebo-controlled study designed to assess the efficacy, safety and tolerability of EP547 in subjects with cholestatic pruritus due to primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC).
  • Intense, unrelenting itch is a common and often debilitating symptom for people living with PBC, PSC and other cholestatic liver diseases.
  • The Phase 2 PACIFIC study will enroll approximately 58 patients with moderate-to-severe pruritus due to PBC or PSC.
  • The companys pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.

Grant Avenue Capital Launches Helios Clinical Research

Retrieved on: 
Thursday, November 17, 2022
Biotechnology, Professional Services, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Finance, Olam, Senior, ICON, Elective surgery, Partnership, ICON plc, CFO, Grant Avenue, Urology, Data collection, Gastroenterology, Medicine, National Institutes of Health, Research, Dermatology, University of North Carolina at Greensboro, Physician, McLindon, Chapel Hill, EBITDA, Growth, University, Contract research organization, Norwich Pharma Services, Business development, MD, Lincoln International, Patient, Health, Vaccine, Pharmaceutical industry, Management, Helios, Alluc, IQVIA

Grant Avenue Capital, LLC (Grant Avenue), a middle market healthcare-focused private equity firm, today announced the launch of Helios Clinical Research (Helios), a new integrated clinical site organization that partners with patients, physicians, and biopharma sponsors to optimize clinical research.

Key Points: 
  • Grant Avenue Capital, LLC (Grant Avenue), a middle market healthcare-focused private equity firm, today announced the launch of Helios Clinical Research (Helios), a new integrated clinical site organization that partners with patients, physicians, and biopharma sponsors to optimize clinical research.
  • Preston Brice, Partner at Grant Avenue, said, We are launching Helios at a time when the need for a centralized solution to accelerate clinical research has never been greater.
  • In addition, the Grant Avenue Foundation supports employees and portfolio companies of Grant Avenue Capital that are actively engaged with healthcare-oriented charitable organizations.
  • Helios Clinical Research is an integrated clinical site organization that partners with patients, physicians and biopharma sponsors to optimize clinical research.

Population Health Leaders Navvis and Esse Health Finalize Merger

Retrieved on: 
Tuesday, November 15, 2022
Health, Hospitals, Practice Management, Other Health, Health Insurance, General Health, Thompson Coburn, PCMH, Allergy, National Committee, Elective surgery, Pediatrics, Home, Urology, American Academy of Child and Adolescent Psychiatry, National Committee for Quality Assurance, Multimedia, Gastroenterology, Radiology, Culture, Asthma, Physician, Internal medicine, Medical home, Organization, Polsinelli, Quality assurance, Population health, Patient, Office of Inspector General, U.S. Department of Health and Human Services, Medicine, Healthcare, Health, Navvy, Metro East, St. Louis

A first-of-its-kind company, Surround Care combines innovation with practical applications and proven capabilities to accelerate the change needed across health systems, physician enterprises, and health plans in population health and value-based care.

Key Points: 
  • A first-of-its-kind company, Surround Care combines innovation with practical applications and proven capabilities to accelerate the change needed across health systems, physician enterprises, and health plans in population health and value-based care.
  • The combination of Navvis and Esse Health will advance population health to a whole new level.
  • Advisors to the Navvis and Esse Health merger were Polsinelli PC, Raymond James Financial, Inc, and Thompson Coburn LLP.
  • Esse Health is a recognized leader in using technology in health care and physician accountability for both quality and cost of care.

9th Annual ModMed User Conference Set to Be Its Largest

Retrieved on: 
Tuesday, November 15, 2022
Software, Practice Management, General Health, Health, Data Management, Hospitals, Health Technology, Technology, Zubin Damania, Podiatry, Ophthalmology, Allergy, Elective surgery, Pain management, Health information management, RCM, Conference, Multimedia, Gastroenterology, National Association Medical Staff Services, Dermatology, Physician, EHR, Practice management, Otorhinolaryngology, Blog, OBGYN, Patient, Video game, Medicine

The ModMed annual user conference MOMENTUM is set to bring together physicians, medical staff, healthcare leaders and other experts for a three-day, interactive live event, November 1820, 2022.

Key Points: 
  • The ModMed annual user conference MOMENTUM is set to bring together physicians, medical staff, healthcare leaders and other experts for a three-day, interactive live event, November 1820, 2022.
  • View the full release here: https://www.businesswire.com/news/home/20221115005466/en/
    9th Annual ModMed User Conference Set to Be Its Largest (Photo: Business Wire)
    MOMENTUM 2022 will be attended by a record 1,100+ providers excited to experience the latest practice software trends and innovations, specialty-specific panels, essential networking events and more.
  • Headlining the ninth annual MOMENTUM users conference is keynote presenter Dr. Zubin Damania, also known as ZDoggMD.
  • ModMed is transforming healthcare by placing doctors and patients at the center of care through an intelligent, specialty-specific cloud platform.

CONMED Corporation Withdraws 2022 Financial Outlook due to Temporary Impact from Software Implementation; Provides 2023 Financial Outlook

Retrieved on: 
Tuesday, November 15, 2022
Surgery, General Health, Health, Medical Devices, Health Technology, Technology, Other Technology, Other Health, Elective surgery, GAAP, Surgeon, Software, Sumathi Best Television Current Reporting Award, Risk, Gynaecology, Government, Name, NYSE, Gastroenterology, Acquisition, General surgery, Physician, Annual report, COVID-19, Comprehensive income, Special-purpose acquisition company, Risk management

CONMED Corporation (NYSE: CNMD) today announced that due to a temporary disruption resulting from the implementation of new warehouse management software, the Company is withdrawing its previously issued full-year 2022 financial outlook.

Key Points: 
  • CONMED Corporation (NYSE: CNMD) today announced that due to a temporary disruption resulting from the implementation of new warehouse management software, the Company is withdrawing its previously issued full-year 2022 financial outlook.
  • In recent weeks, the Company began implementing new software designed to increase the efficiency and performance of its primary distribution facility.
  • The withdrawal of the full-year 2022 financial outlook is solely attributable to the impact of this software implementation.
  • CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures.